Lavipharm S.A. (ATH:LAVI)

Greece · Delayed Price · Currency is EUR

1.538

-0.014 (-0.90%)

Jul 1, 2026, 5:18 PM EET

92.49% (1Y)

Market Cap	262.66M +97.1%
Revenue (ttm)	64.53M +23.0%
Net Income	5.18M -45.5%
EPS	0.03
Shares Out	170.78M
PE Ratio	51.51
Forward PE	n/a
Dividend	0.02 (1.29%)
Ex-Dividend Date	Jul 20, 2026

Volume	30,959
Open	1.542
Previous Close	1.552
Day's Range	1.530 - 1.578
52-Week Range	0.756 - 1.738
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1911

Employees 285

Stock Exchange Athens Stock Exchange

Ticker Symbol LAVI

Full Company Profile

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.

Financial Statements